Allos Therapeutics News

Recently Allos Therapeutics Inc. submitted a request to the European Medicines Agency seeking a review of the negative opinion issued by the EMA's Committee for Medicinal Products for Human Use regarding the company's sole marketed product Folotyn .

The recommendation earlier this month by the EMA's Committee for Medicinal Products for Human Use was against conditional approval of Folotyn for the treatment of European patients with peripheral T-cell lymphoma whose disease has progressed after at least one systemic therapy.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia Allos Therapeutics, Inc.

Allos Therapeutics, Inc. today reported interim results from the Company's ongoing Phase 1 combination study of FOLOTYN and bexarotene in patients with relapsed or refractory cutaneous T-cell lymphoma .

Allos Therapeutics Incorporated was downgraded by JPMorgan Chase & Co. from an "overweight" rating to a "neutral" rating in a research note issued on Monday.

For nearly 30 years, Cancer Treatment Centers of American has been dedicated to finding the right combination of personalized cancer treatments for their patients.

BUYINS.NET: Market Maker Surveillance Report. SIRI, ALTH, WFC, CHRS, MCHP, DCT, Bearishly Biased Price Friction For Thursday, January 19th 2012 BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday.

The recommendation by the EMA's Committee for Medicinal Products for Human Use applied to PTCL patients whose disease has progressed after at least one systemic therapy, the Westminster-based biotech company said.